Todos Medical announced that it has received and analyzed data from the University of Leipzig on the lymphocyte proliferation test, which demonstrated a strong correlation between LymPro and amyloid PET. Upon review of the LymPro data, Todos Medical exercised its exclusive option to acquire the remaining 80.01% of its joint venture Breakthrough Diagnostics from Amarantus Bioscience Holdings. The transaction is expected to close upon listing of Todos’ common stock on a national stock exchange.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.